Independent MARA® Ratings quantify HTA reimbursement risk for pharma assets. 5-year 97% precision across 10 domains. Request your report today.

MARA Rating Insight Since 2020, assets averaging a 2.9 Comparator Selection score sailed through HTA reviews, while those at 2.6 faced more rejections and extra data requests. That 0.3-point gap can make—or break—your credibility in payer eyes.

Did you know? At MARA Rating, we translate comparator requirements from NICE (UK), G-BA/IQWiG (Germany) and ICER (US) into a focused A++ to C score—now applied to 350+ assets. Proper comparator choice is essential to show value where it really counts.

What Is Comparator Selection? It evaluates how well your trials stack up against the real-world standard of care:

• Relevance to SOC: Did you use the locally accepted first-line therapy as control?
• Clinical Equivalence/Similarity: When active comparators weren’t feasible, were indirect or network meta-analyses robust?
• Inclusion in Guidelines: Did your comparator match those endorsed by clinical guidelines or prior HTA decisions?
• Multiple Comparators: For settings with more than one SOC, did you cover all key alternatives?
• Alignment with Practice: Were comparator doses, regimens and settings reflective of actual patient care? MARA Scoring Framework …

Strong vs. Marginal Scores

• A++ / A+ / A (“Strong or above”): These assets averaged ≥2.9—trials used gold-standard comparators or credible indirect methods, so HTA bodies accepted analyses without hesitation.
• B++ to C (“Marginal or below”): Assets at ≤2.6 faced skepticism—placebo-only or outdated comparators triggered requests for new analyses or even additional studies.

Even a 0.3-point lift can shift your submission from “need more data” to “approved.”

Actionable Tips by Role

• Market Access Professionals: Map comparator strategy to each target market early—align your control arm with local guidelines and capture any needed indirect comparisons.
• Venture Investors & Acquirers: Prioritize assets with head-to-head data against the prevailing SOC; strong comparator evidence de-risks your portfolio.
• Drug Developers: If multiple SOCs exist, include network meta-analyses or multi-arm trials—explain clearly how each comparator was chosen and why it reflects real practice.

See Your Edge Our anonymized distributions across 350+ assets reveal exactly where your comparator choice stands—and where you need to strengthen your evidence.

Do you know how your product scores? Visit mararating.com or send us a line.

#MarketAccess #HTA #EvidenceStrategy #ComparatorSelection #MARARating #MarketAccessScore